90 related articles for article (PubMed ID: 15667620)
1. Gastrointestinal leukocytoclastic vasculitis: an adverse effect of sirolimus.
Nagarajan S; Friedrich T; Garcia M; Kambham N; Sarwal MM
Pediatr Transplant; 2005 Feb; 9(1):97-100. PubMed ID: 15667620
[TBL] [Abstract][Full Text] [Related]
2. [Use of Sirolimus in five pediatric patients undergoing solid organ transplantation].
Roque E J; Ríos M G; Vignolo A P; Pinochet V C; Schultz M; Humeres A R; Delucchi A; Rius A M; Hepp K J
Rev Med Chil; 2008 May; 136(5):631-6. PubMed ID: 18769812
[TBL] [Abstract][Full Text] [Related]
3. Conversion to sirolimus-based immunosuppression in maintenance liver transplantation patients.
Morard I; Dumortier J; Spahr L; Hadengue A; Majno P; Morel P; Mentha G; Giostra E
Liver Transpl; 2007 May; 13(5):658-64. PubMed ID: 17457887
[TBL] [Abstract][Full Text] [Related]
4. Conversion to sirolimus in pediatric renal transplantation recipients.
Garcia CD; Bittencourt VB; Alves AB; Garcia VD; Tumelero A; Antonello JS; Malheiros D
Transplant Proc; 2006; 38(6):1901-3. PubMed ID: 16908317
[TBL] [Abstract][Full Text] [Related]
5. Late conversion from calcineurin inhibitor-based to sirolimus-based immunosuppression due to chronic toxicity: a prospective study with protocol biopsy amendment.
Uslu A; Töz H; Sen S; Alkan FT; Nart A; Aykas A; Doğan M; Postaci H; Sahin T; Simşek C
Transplant Proc; 2009 Mar; 41(2):756-63. PubMed ID: 19328973
[TBL] [Abstract][Full Text] [Related]
6. Comparison of sirolimus plus tacrolimus versus sirolimus plus cyclosporine in high-risk renal allograft recipients: results from an open-label, randomized trial.
Gaber AO; Kahan BD; Van Buren C; Schulman SL; Scarola J; Neylan JF;
Transplantation; 2008 Nov; 86(9):1187-95. PubMed ID: 19005398
[TBL] [Abstract][Full Text] [Related]
7. Long-term results in renal transplant patients with allograft dysfunction after switching from calcineurin inhibitors to sirolimus.
Bumbea V; Kamar N; Ribes D; Esposito L; Modesto A; Guitard J; Nasou G; Durand D; Rostaing L
Nephrol Dial Transplant; 2005 Nov; 20(11):2517-23. PubMed ID: 15985508
[TBL] [Abstract][Full Text] [Related]
8. Sirolimus-induced leukocytoclastic vasculitis.
Hardinger KL; Cornelius LA; Trulock EP; Brennan DC
Transplantation; 2002 Sep; 74(5):739-43. PubMed ID: 12352895
[TBL] [Abstract][Full Text] [Related]
9. Center experience in liver transplantation (LTX): management of dermal side effects caused by sirolimus.
Schaffellner S; Jakoby E; Kniepeiss D; Stadlbauer V; Duller D; Iberer F; Tscheliessnigg KH
Int Immunopharmacol; 2005 Jan; 5(1):137-40. PubMed ID: 15589473
[TBL] [Abstract][Full Text] [Related]
10. Successful treatment of post-renal transplant gastric and pulmonary Kaposi's sarcoma with conversion to rapamycin treatment.
Charfi S; Krichen-Makni S; Yaich S; Makni H; Khabir A; Amouri A; Charfeddine K; Hachicha J; Sellami-Boudawara T
Saudi J Kidney Dis Transpl; 2007 Nov; 18(4):617-20. PubMed ID: 17951954
[TBL] [Abstract][Full Text] [Related]
11. Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial.
Schena FP; Pascoe MD; Alberu J; del Carmen Rial M; Oberbauer R; Brennan DC; Campistol JM; Racusen L; Polinsky MS; Goldberg-Alberts R; Li H; Scarola J; Neylan JF;
Transplantation; 2009 Jan; 87(2):233-42. PubMed ID: 19155978
[TBL] [Abstract][Full Text] [Related]
12. Proteinuria after conversion to sirolimus in renal transplant recipients.
Sahin GM; Sahin S; Kantarci G; Ergin H
Transplant Proc; 2006 Dec; 38(10):3473-5. PubMed ID: 17175308
[TBL] [Abstract][Full Text] [Related]
13. Absence of proteinuria predicts improvement in renal function after conversion to sirolimus-based immunosuppressive regimens in lung transplant survivors with chronic kidney disease.
Stephany BR; Boumitri M; Budev M; Alao B; Poggio ED
J Heart Lung Transplant; 2009 Jun; 28(6):564-71. PubMed ID: 19481016
[TBL] [Abstract][Full Text] [Related]
14. Localized vasculitis of the gastrointestinal tract.
Garcia-Porrua C; Gutierrez-Duque O; Soto S; Garcia-Rodeja E; Gonzalez-Gay MA
Semin Arthritis Rheum; 2006 Jun; 35(6):403-6. PubMed ID: 16765718
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of the efficacy and safety of a slow conversion from calcineurin inhibitor- to sirolimus-based therapies in maintenance renal-transplant patients presenting with moderate renal insufficiency.
Kamar N; Frimat L; Blancho G; Wolff P; Delahousse M; Rostaing L
Transpl Int; 2007 Feb; 20(2):128-34. PubMed ID: 17239020
[TBL] [Abstract][Full Text] [Related]
16. Replacement of calcineurin-inhibitors with sirolimus as primary immunosuppression in stable cardiac transplant recipients.
Raichlin E; Khalpey Z; Kremers W; Frantz RP; Rodeheffer RJ; Clavell AL; Edwards BS; Kushwaha SS
Transplantation; 2007 Aug; 84(4):467-74. PubMed ID: 17713429
[TBL] [Abstract][Full Text] [Related]
17. Sirolimus exposure during the early post-transplant period reduces the risk of CMV infection relative to tacrolimus in renal allograft recipients.
Haririan A; Morawski K; West MS; El-Amm JM; Doshi MD; Cincotta E; Alangaden GJ; Chandrasekar P; Gruber SA
Clin Transplant; 2007; 21(4):466-71. PubMed ID: 17645705
[TBL] [Abstract][Full Text] [Related]
18. Sirolimus monotherapy in liver transplantation.
Di Benedetto F; Di Sandro S; De Ruvo N; Masetti M; Montalti R; Romano A; Guerrini GP; Ballarin R; De Blasiis MG; Gerunda GE
Transplant Proc; 2007; 39(6):1930-2. PubMed ID: 17692656
[TBL] [Abstract][Full Text] [Related]
19. Sirolimus in chronic allograft nephropathy in pediatric recipients.
Ibáñez JP; Monteverde ML; Diaz MA; Goldberg J; Turconi AF
Pediatr Transplant; 2007 Nov; 11(7):777-80. PubMed ID: 17910656
[TBL] [Abstract][Full Text] [Related]
20. Proteinuria in transplant patients associated with sirolimus.
Franco AF; Martini D; Abensur H; Noronha IL
Transplant Proc; 2007 Mar; 39(2):449-52. PubMed ID: 17362756
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
